- Reaction score
- 224
Dug up some cool research on prolactin (PRL) and its effects on scalp hair loss.
Calcineurin upregulates PRL receptor expression in human HFs
We already knew that our old friend Cyclosporine A inhibits calcineurin, and thereby potently upregulates stem cell (SC) differentiation. From the article:
More studies then. Bad news for E2 (and thyrotropin).
E2 increases PRL secretion and PRL receptor density in HFs
In conclusion, PRL receptor density is downregulated by CsA, but it is not a PRL receptor antagonist (so far, only the experimental antibody is). CsA increases SC differentiation and promotes anagen. It is unknown if other CN inhibitors like Tacrolimus can promote anagen to a similar extent as CsA, but they should all be able to potently downregulate PRL receptor density. Safety concerns aside, this makes them interesting compounds to consider for topical hairloss formulations (apart from its PRLr downregulating effect, CsA also inhibits sFRP1 (inducing the Wnt pathway) and inhibits several interleukins (ILs), thereby directly increasing SC differentiation and suppressing inflammitory responses).
Calcineurin upregulates PRL receptor expression in human HFs
We already knew that our old friend Cyclosporine A inhibits calcineurin, and thereby potently upregulates stem cell (SC) differentiation. From the article:
Then, the study continues to identify a previously unknown relation to prolactin:One key regulator of SC activity in the HF is the transcription factor nuclear factor of activated T cells c1 (Nfatc1), which is expressed in bulge SCs (Tumbar et al. 2004; Rhee et al. 2006; Horsley et al. 2008). Nfatc1 activity is directly regulated by the phosphatase calcineurin (CN), which dephosphorylates Nfatc1 to induce its nuclear translocation and transcriptional activity (Rao et al. 1997; Horsley and Pavlath 2002). Inactivation of Nfatc1 through skin-specific genetic knockout or treatment with cyclosporine A (CSA), an inhibitor of CN (Mattila et al. 1990), results in precocious activation of HF growth in mice (Paus et al. 1989; Gafter-Gvili et al. 2003; Horsley et al. 2008).
In simpler terms, calcineurin is at the start of this CN-Nfatc1-PRL-Stat5 axis. Thus, CN upregulates PRL receptor density, whereas Cyclosporine A directly kills the entire pathway. So far, CsA is the only compound that I ran across that directly downregulates PRL receptors. The study also continues to show that PRL, and by extension Stat5 induces "SC quiescence", which is the same as shortening anagen/inducing catagen in HFs (which we already knew). More on the catagen inducing effects of PRL can be read here, among others.In this study, we identified genetic changes associated with SC activation following administration of CSA, a robust activator of follicular SCs. Gene expression profiling revealed a novel molecular interplay between Nfatc1 and Prlr, implicating Prl signaling as a regulator of SC activity in the hair. Using pharmacological and genetic experiments in mice, we revealed that Prl signaling and Nfatc1 expression are required for the abrogation of hair growth during pregnancy. Furthermore, we demonstrated that direct administration of Prl promotes HF quiescence. Finally, we showed that Prl signaling activates Jak/Stat5 signaling in follicular SCs to maintain their dormancy. Our findings unveil a novel CN–Nfatc1–Prlr–Stat5 pathway that governs skin SC quiescence downstream from a systemic hormone.
More studies then. Bad news for E2 (and thyrotropin).
E2 increases PRL secretion and PRL receptor density in HFs
This was at concentrations of 100nM, which can be achieved by a 1mcg/mL E2 topical. It is unknown what concentrations are achieved with oral/transdermal full HRT, because serum concentrations do not necessarily correspond to scalp concentrations. Of course, the positive effects of E2 will (massively) override the negative effects it has on PRL secretion (as shown in other papers mentioned in other posts of mine), but still it is something to be aware of. PRL should ideally be reduced (and receptors be blocked to prevent upregulation).Oestrogen treatment significantly upregulated PRL and PRLR immunoreactivity in selected skin and hair follicle compartments, at the gene and protein level (P < 0.05).
In conclusion, PRL receptor density is downregulated by CsA, but it is not a PRL receptor antagonist (so far, only the experimental antibody is). CsA increases SC differentiation and promotes anagen. It is unknown if other CN inhibitors like Tacrolimus can promote anagen to a similar extent as CsA, but they should all be able to potently downregulate PRL receptor density. Safety concerns aside, this makes them interesting compounds to consider for topical hairloss formulations (apart from its PRLr downregulating effect, CsA also inhibits sFRP1 (inducing the Wnt pathway) and inhibits several interleukins (ILs), thereby directly increasing SC differentiation and suppressing inflammitory responses).
Last edited: